Aim of the Study: European Association of Urology, National Comprehensive Cancer Network and American Urological Association provide follow-up guidelines for surgically treated Renal Cell Carcinoma (RCC). However, these guidelines are not supported by good quality evidence. The potential exposure of the patients (pts) to the risks connected to unnecessary ionizing radiations is an important factor to consider. Aim of this study was to evaluate the oncological outcomes in a large cohort of pts to better tailor follow-up schedules of pts that underwent surgery for RCC. Materials and Methods: We enrolled 1932 pts surgically treated for sporadic pT1 pN0, M0 RCC from 7 Italian Accademic Centers with minimum follow-up of 6 months. The exclusion criteria were: high nuclear grade, presence of intratumoural necrosis, lymphovascular invasion, collecting system invasion, rare histological RCC subtype and positive surgical margin. Recurrences were classified in accordance to their location: abdomen, chest, multiple districts and other sites (including central nervous system, bone and skin). Results: Median age of the pts was 60 years (53–70). 1174 pts underwent partial nephrectomy and 758 radical nephrectomy. Histological subtype of the specimens were: 1491 Clear Cell RCC (ccRCC), 244 papillary RCC (pRCC) and 197 chromopobe RCC (chRCC). Median follow-up was 90 months (36–125). 145 (7,5%) pts developed a recurrence. Site and rate of recurrences are reported in Table 1. Statistical analysis identifies a significant difference in the incidence of all site recurrences among all histological subtypes (P = 0,0017); significant statistical difference was observed also in the incidence of primary chest recurrences for all histological subtypes (P = 0,002). In the chRCC subgroup no chest recurrences were observed. 20 pts with ccRCC have a chest recurrence, 13 of them more than 5 years from surgery

It is time to differentiate the follow-up schedule of low-risk renal cell carcinoma according to the histological subtype

Rizzo, M.;Umari, P.;LA VOLPE, ADRIANA;ANTONELLI, ANTONINO;PALUMBO, CHIARA;Cancellieri, L.;Verzotti, E.;Pavan, N.;MARI, GIULIA AURORA;Liguori, G.;
2018

Abstract

Aim of the Study: European Association of Urology, National Comprehensive Cancer Network and American Urological Association provide follow-up guidelines for surgically treated Renal Cell Carcinoma (RCC). However, these guidelines are not supported by good quality evidence. The potential exposure of the patients (pts) to the risks connected to unnecessary ionizing radiations is an important factor to consider. Aim of this study was to evaluate the oncological outcomes in a large cohort of pts to better tailor follow-up schedules of pts that underwent surgery for RCC. Materials and Methods: We enrolled 1932 pts surgically treated for sporadic pT1 pN0, M0 RCC from 7 Italian Accademic Centers with minimum follow-up of 6 months. The exclusion criteria were: high nuclear grade, presence of intratumoural necrosis, lymphovascular invasion, collecting system invasion, rare histological RCC subtype and positive surgical margin. Recurrences were classified in accordance to their location: abdomen, chest, multiple districts and other sites (including central nervous system, bone and skin). Results: Median age of the pts was 60 years (53–70). 1174 pts underwent partial nephrectomy and 758 radical nephrectomy. Histological subtype of the specimens were: 1491 Clear Cell RCC (ccRCC), 244 papillary RCC (pRCC) and 197 chromopobe RCC (chRCC). Median follow-up was 90 months (36–125). 145 (7,5%) pts developed a recurrence. Site and rate of recurrences are reported in Table 1. Statistical analysis identifies a significant difference in the incidence of all site recurrences among all histological subtypes (P = 0,0017); significant statistical difference was observed also in the incidence of primary chest recurrences for all histological subtypes (P = 0,002). In the chRCC subgroup no chest recurrences were observed. 20 pts with ccRCC have a chest recurrence, 13 of them more than 5 years from surgery
EUROPEAN UROLOGY. SUPPLEMENTS
https://www.sciencedirect.com/science/article/pii/S1569905618333426?via%3Dihub
File in questo prodotto:
File Dimensione Formato  
rizzo2018 (1).pdf

non disponibili

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 91.92 kB
Formato Adobe PDF
91.92 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11368/2936196
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact